PMID- 15460176
OWN - NLM
STAT- MEDLINE
DCOM- 20041202
LR  - 20190917
IS  - 0277-0008 (Print)
IS  - 0277-0008 (Linking)
VI  - 24
IP  - 9
DP  - 2004 Sep
TI  - Potential in vitro interaction between tenecteplase and unfractionated heparin.
PG  - 1154-8
AB  - STUDY OBJECTIVE: To explore the potential of a direct drug interaction between 
      unfractionated heparin (UFH) and tenecteplase that lowers the pharmacologic 
      propensity of UFH to prolong the activated partial thromboplastin time (aPTT). 
      DESIGN: In vitro experiment. SETTING: Texas Tech University School of Pharmacy, 
      with sample analysis performed at an independent, contract laboratory. Samples. 
      Blood samples collected from healthy volunteers. INTERVENTION: Three separate in 
      vitro experiments were conducted to explore the relative influence of various 
      thrombolytic agents with and without UFH on aPTT prolongation. In each 
      experiment, blood from healthy volunteers (12 for each experiment) was treated 
      with different concentrations and combinations of tenecteplase and UFH. 
      MEASUREMENTS AND MAIN RESULTS: When the effects of tenecteplase plus UFH versus 
      UFH alone on aPTT prolongation were compared, each experiment demonstrated 
      attenuation of aPTT with the combination versus UFH alone. In contrast, findings 
      for other thrombolytic agents combined with UFH demonstrate elevation of the aPTT 
      compared with UFH alone. CONCLUSION: The results indicate a possible drug 
      interaction between tenecteplase and UFH, with tenecteplase attenuating the 
      intensity of anticoagulation of UFH in vitro. Further investigation into this 
      possible interaction is warranted in the clinical setting.
FAU - Tsikouris, James P
AU  - Tsikouris JP
AD  - Schools of Pharmacy, Texas Tech University Health Sciences Center, Lubbock, Texas 
      79430, USA. james.tsikouris@ttuhsc.edu
FAU - Martin, Christopher P
AU  - Martin CP
FAU - Cox, Craig D
AU  - Cox CD
FAU - Ziska, Martin
AU  - Ziska M
FAU - Suarez, Jose A
AU  - Suarez JA
FAU - Meyerrose, Gary E
AU  - Meyerrose GE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Fibrinolytic Agents)
RN  - 9001-32-5 (Fibrinogen)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
RN  - WGD229O42W (Tenecteplase)
SB  - IM
MH  - Drug Interactions
MH  - Fibrinogen/*drug effects
MH  - Fibrinolytic Agents/*pharmacology
MH  - Heparin/*pharmacology
MH  - Humans
MH  - In Vitro Techniques
MH  - *Partial Thromboplastin Time
MH  - Tenecteplase
MH  - Tissue Plasminogen Activator/*pharmacology
EDAT- 2004/10/06 09:00
MHDA- 2004/12/16 09:00
CRDT- 2004/10/06 09:00
PHST- 2004/10/06 09:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/10/06 09:00 [entrez]
AID - 10.1592/phco.24.13.1154.38097 [doi]
PST - ppublish
SO  - Pharmacotherapy. 2004 Sep;24(9):1154-8. doi: 10.1592/phco.24.13.1154.38097.